Citations

Clear

7 citation(s) found for "Brown, Diane".

Phenobarbital Versus Benzodiazepine‐Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta‐Analysis
Rizwan, Zeeshan, Brown, Diane , Barry, Simone , Guppy, Kern, Gerberi, Dana , Gajic, Ognjen , Herasevich, Svetlana , Rizwan, Zeeshan M , Gerberi, Danielle J , Gajic, Ognjen , Guppy, Kern H.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | August 24, 2026 | Volume: 46 | Issue: 9 | Pages: No page available

10.1002/phar.70197 | PMID 42634386 Get It

ABSTRACT Objective To compare outcomes of phenobarbital‐based versus benzodiazepine‐based pathways for alcohol withdrawal syndrome (AWS) in critically ill adults and evaluate whether pathway design and timing of phenobarbital use affect treatment outcomes. Data Sources A librarian‐led search of MEDLINE, Embase, Cochrane Central, CINAHL, Web of Science, Scopus, ClinicalTrials.gov , and the World Health Organization International Clinical Trials Registry Platform was conducted through July 2024, with updates in December 2024, August 2025, and December 2025. Search concepts included phenobarbital, benzodiazepines, and alcohol withdrawal. Study Selection and Data Extraction Comparative studies of adults admitted or transferred to an intensive care unit (ICU) with AWS and treated with phenobarbital‐based versus benzodiazepine‐based pathways were included. Sixteen nonrandomized studies were included in the qualitative synthesis, and 12 treatment‐oriented studies were included in the primary meta‐analysis. Multiple reviewers independently screened studies, extracted data, and assessed risk of bias using Risk Of Bias In Non‐randomized Studies—of Interventions (ROBINS‐I). Data Synthesis Phenobarbital‐based pathways were not associated with significantly different intubation (11 studies; odds ratio (OR), 0.62; 95% confidence interval (CI), 0.20–1.87; I 2 = 73%) or hospital length of stay (five studies; mean differences [MD], −1.75 days; 95% CI, −5.07 to 1.56; I 2 = 63%) compared with benzodiazepine‐based pathways. ICU length of stay was shorter with phenobarbital‐based pathways (eight studies; MD, −0.60 days; 95% CI, −0.79 to −0.41; I 2 = 0%). In exploratory subgroup analyses, front‐loaded, protocolized phenobarbital‐first pathways were associated with lower intubation and shorter hospital length of stay, but certainty of evidence was very low. Relevance to Patient Care and Clinical Practice This review distinguishes phenobarbital‐first, protocolized ICU pathways from adjunctive or mixed phenobarbital strategies, suggesting that implementation design may influence outcomes. Conclusions Although evidence remains very low certainty, these findings suggest that phenobarbital's role in ICU AWS may be pathway dependent. Front‐loaded, protocolized phenobarbital‐first pathways may be associated with favorable outcomes in exploratory analyses, but these findings should be considered hypothesis‐generating and require confirmation in prospective randomized trials. Trial Registration: CRD42024595819
1465: MONOTHERAPY PHENOBARBITAL VS BENZODIAZEPINES FOR AWS IN ICU: A SYSTEMATIC REVIEW AND META-ANALYSIS
Rizwan, Zeeshan, Brown, Diane , Kern, Guppy, Rizwan, Zeeshan M , Barry, Simone , Kern, Guppy

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001104524.53744.39 Get It

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
Belch, Andrew R. , White, Darrell , Cheung, Matthew C. , Chen, Christine , Shustik, Chaim, Song, Kevin , Tosikyan, Axel, Brown, Diane , Robinson, Suzanne, Srinivasan, Shankar , Belch, Andrew , Cheung, Matthew , Bahlis, Nizar Jacques , Dispenzieri, Angela , Anderson, Kenneth C. , Facon, Thierry T.F.

Mayo Clinic

Cancer Medicine | October 13, 2020 | Volume: 9 | Issue: 23 | Pages: 8923-8930

10.1002/cam4.3511 | PMID 33049118 Get It

AbstractThe phase 3 FIRST trial demonstrated significant improvement in progression‐free survival (PFS) and overall survival (OS) with an immune‐stimulatory agent, lenalidomide, in combination with low‐dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). Rd continuous similarly extended PFS vs fixed‐duration Rd for 18 cycles (Rd18). Outcomes in the Canadian/US subgroup (104 patients per arm) are reported in this analysis. Rd continuous demonstrated a significant improvement in PFS vs MPT (median, 29.3 vs 20.2 months; HR, 0.69 [95% CI, 0.49‐0.97]; p = 0.03326) and an improvement vs Rd18 (median, 21.9 months). Median OS was 56.9 vs 46.8 months with Rd continuous vs MPT (p = 0.15346) and 59.5 months with Rd18. The overall response rate was higher with Rd continuous and Rd18 (78.8% and 79.8%) vs MPT (65.4%). In the 49.0%, 52.9%, and 29.8% of patients with at least very good partial response in the Rd continuous, Rd18, and MPT arms, respectively, the median PFS was 56.0, 30.9, and 40.2 months, respectively. The most common grade 3/4 treatment‐emergent adverse events were neutropenia (28.4%, 30.1%, and 52.0%), anemia (23.5%, 21.4%, and 23.5%), and infections (37.3%, 30.1%, and 24.5%) with Rd continuous, Rd18, and MPT, respectively. These results were consistent with those in the intent‐to‐treat population, confirming the benefit of Rd continuous vs MPT in the Canadian/US subgroup and supporting the role of Rd continuous as a standard of care for transplant‐ineligible patients with NDMM.
Effects of Hemoglobin C and S Traits on Eight Glycohemoglobin Methods
Roberts, William L. , De, Barun K., Brown, Diane , Hanbury, C Michael, Hoyer, James D., John, W. Garry , Lambert, Thomas L, Lundell, Ryan , Rohlfing, Curt L., Brown, Diane, Little, Randie R.

Mayo Clinic

Clinical Chemistry | January 23, 2020 | Volume: 48 | Issue: 2 | Pages: 383-385

10.1093/clinchem/48.2.383 Get It

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Belch, Andrew R. , White, Darrell , Cheung, M., Chen, C., Shustik, Chaim, Song, Kevin , Tosikyan, Axel, Kotey, Stanley, Brown, Diane , Srinivasan, S. , Bahlis, Nizar Jacques , Cheung, M., Dispenzieri, Angela , Anderson, Kenneth C. , Brown, D., Robinson, S., Facon, Thierry T.F.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 962

10.1097/01.hs9.0000567032.31064.27 Get It

Background:The pivotal FIRST trial, the largest study conducted in transplant‐ineligible (TNE) patients (pts) with newly diagnosed multiple myeloma (NDMM), examined lenalidomide plus low‐dose dexamethasone until disease progression (Rd continuous), Rd for 18 cycles (Rd18), and melphalan, prednisone, and thalidomide (MPT). The study, conducted in 18 countries in Europe, North America, and Asia Pacific, demonstrated that Rd continuous significantly improved progression‐free survival (PFS) vs MPT (median 26.0 vs 21.9 mos; HR, 0.69; 95% CI, 0.59‐0.79; P < .00001). PFS was similarly extended for Rd continuous vs Rd18 (median 21.0 mos; HR, 0.70; 95% CI, 0.60‐0.81). Furthermore, median overall survival (OS) was significantly longer with Rd continuous vs MPT (median 59.1 vs 49.1 mos; HR, 0.78; 95% CI, 0.67‐0.92; P = .0023). These results support the use of frontline oral, alkylator‐free continuous therapy for TNE NDMM pts and established Rd continuous as a standard of care as reflected by clinical guidelines in Canada, the US, and Europe.Aims:To report outcomes in the subset of patients from Canada and the US.MethodsPts with TNE NDMM were randomized 1:1:1 to Rd continuous (with lenalidomide given on days 1‐21 of 28‐day cycles until disease progression), Rd18 (with lenalidomide given on days 1‐21 of eighteen 28‐day cycles), or MPT (twelve 42‐day cycles). Rd18 and MPT were both 72 weeks in duration. Stratification factors included country and Rd continuous vs MPT was the primary comparison. The primary endpoint was PFS and secondary endpoints included OS, time to next therapy (TTNT) and safety. Time from randomization to second progression or death (PFS2) was an exploratory analysis. Response assessment used for PFS and PFS2 analysis was determined by investigators based on International Myeloma Working Group criteria. Data is presented as of the January 21, 2016 cutoff used for the final OS analysis.Results:A total of 312 pts from Canada (n = 252) and the US (n = 60) were enrolled (104 in each arm). Consistent with results from the intent‐to‐treat (ITT) analysis, the Canada/US subgroup also demonstrated a significant improvement in PFS with Rd continuous vs MPT (median 29.3 vs 20.2 mos; HR, 0.69; 95% CI, 0.49‐0.97; P = .03326) and an improvement vs Rd18 (median 21.9 mos; HR, 0.72; 95% CI, 0.51‐1.02; Table). Median OS was 56.9 vs 46.8 mos for Rd continuous vs MPT (HR, 0.77; 95% CI, 0.53‐1.11; P = .15346). Median PFS2 was longer for Rd continuous vs MPT (median 39.3 vs 35.1 mos; HR, 0.69; 95% CI 0.50‐0.95) as was TTNT (median 39.1 vs 24.6 mos; HR, 0.54; 95% CI, 0.37‐0.78). Additional details, including safety data, will be presented at the meeting.Summary/Conclusion:In the Canada/US subpopulation of pts from FIRST, Rd continuous extended median PFS by 9 mos vs MPT and > 7 mos vs Rd18. Rd continuous also delayed median TTNT > 14 mos and resulted in a longer PFS2 vs MPT, suggesting that the benefit from frontline Rd continuous is maintained at relapse. These results are consistent with that from the ITT population confirming the advantage of Rd continuous vs MPT in the Canada/US subgroup and supporting the role of Rd continuous as a standard of care for TNE pts with NDMM. The efficacy observed with Rd continuous raises the question on the role of immunostimulatory effects by the immunomodulatory agents in NDMM.image
Geriatrics Education Team Model Results in Sustained Geriatrics Training in 15 Residency and Fellowship Programs and Scholarship
Denson, Steven, Denson, Kathryn , Brown, Diane , Manzi, Gabriel, Rehm, Judith, Wessel, Bambi, Duthie, Edmund H., Simpson, Deborah

Mayo Clinic

Journal of the American Geriatrics Society | March 29, 2016 | Volume: 64 | Issue: 4 | Pages: 855-861

10.1111/jgs.14040 | PMID 27021702 Get It

Caring for the growing elderly population will require specialty and subspecialty physicians who have not completed geriatric medicine fellowship training to participate actively in patient care. To meet this workforce demand, a sustainable approach to integrating geriatrics into specialty and subspecialty graduate medical education training is needed. This article describes the use of a geriatrics education team ( GET ) model to develop, implement, and sustain specialty‐specific geriatrics curricula using a systematic process of team formation and needs assessment through evaluation, with a unique focus on developing curricular interventions that are meaningful to each specialty and satisfy training, scholarship, and regulatory requirements. The GET model and associated results from 15 specialty residency and fellowship training programs over a 4‐year period include 93% curriculum sustainability after initial implementation, more than half of the programs introducing additional geriatrics education, and more than 80% of specialty GET s fulfilling their scholarship requirements through their curriculum dissemination. Win–wins and barriers encountered in using the GET model, along with the model's efficacy in curriculum development, sustainability, and dissemination, are summarized.
Activity enhances dopaminergic long-duration response in Parkinson disease
Kang, Un Jung , Auinger, Peggy , Fahn, Stanley, Oakes, David , Shoulson, Ira , Kieburtz, Karl, Rudolph, Alice, Seibyl, John , Olanow, C. Warren , Tanner, Caroline M., Schifitto, Giovanni , Zhao, Hongwei , Reyes, Lydia, Shinaman, Aileen, Comella, Cynthia L., Blasucci, Lucia M., Samanta, Johan, Stacy, Mark, Williamson, Kelli, Harrigan, Mary, Greene, Paul, Ford, Blair, Moskowitz, Carol, Truong, Daniel , Pathak, Mayank , Jankovic, Joseph, Ondo, William G. , Atassi, Farah, Hunter, Christine , Jacques, Carol, Lannon, Margaret C., Russell, David , Jennings, Danna , Fussell, B., Schwarzschild, Michael A. , Growdon, John H., Tennis, Marsha, Gauthier, Serge , Panisset, Michel , Hall, Jean, Gancher, Stephen T., Hammerstad, John P., Stone, Claudia, Alexander-Brown, Barbara, Molho, Eric , Brown, Diane, Evans, Sharon, Manyam, Bala V., Simpson, Patricia , Wulbrecht, Brian, Whetteckey, Jacqueline, Roberts, Ted E, King, Pamela, Zesiewicz, Theresa A. , Gauger, Lisa, Trugman, Joel M. , Wooten, G. Frederick, Rost‐Ruffner, Elke, Suchowersky, Oksana , Ranawaya, Ranjit, Wood, Susan M. , Pantella, Carol , Kurlan, Roger, Richard, Irene Hegeman, Pearson, N. Shirlene, Caviness, John N., Adler, Charles, Lind, Marlene, Siderowf, Andrew , Colcher, Amy, Lloyd, Mary, Weiner, William J., Shulman, Lisa M. , Koller, William C., Lyons, Kelly , Feldman, Robert G., Ellias, Samuel A., Thomas, Cathi-Ann, Juncos, Jorge L., Watts, Ray L., Partlow, Anna, Tetrud, James W., Togasaki, Daniel M., Stewart, Tracy, Mark, Margery H., Sage, Jacob I., Caputo, Debbie, Gould, Harry J. , Rao, Jayaraman, McKendrick, A. D., Brin, Mitchell F. , Danisi, Fabio , Benabou, Reina, Hubble, Jean, Paulson, George W., Reider, Carson, Birnbaum, Alex, So, Julie , Dubinsky, Richard , Uitti, Ryan J. , Turk, Margaret F., Rottenberg, David A., Hansen, Joy, Ramos, Serrano, Waters, Cheryl , Lew, Mark, Welsh, Mickie, Kawai, Connie, OʼBrien, Christopher , Kumar, Rajeev , Seeberger, Lauren , Judd, Deborah, Mendis, Tilak, Grimes, David A. , Sutherland, Laura, Dawson, Ted M. , Reich, Stephen G. , Frey, Kirk A. , Wernette, K., Marek, Kenneth , Lang, Anthony E. , Goetz, Christopher G. , Jankovic, Joseph, Friedman, Joseph H. , Standaert, David G. , Factor, Stewart Alan , Clark, Jeffrey N. , Martin, W. R. Wayne , Hauser, Robert A. , Perlmutter, Joel S. , Racette, Brad A. , Simuni, Tanya , Saint‐Hilaire, Marie , Miyasaki, Janis M. , Johnston, Lisa , Pahwa, Rajesh , Wszołek, Zbigniew K. , Tuite, Paul , Barclay, Corlane , Dunlop, Rebecca A. , Albin, Roger L.

Mayo Clinic

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675 Get It